Abstract

Noninvasive preimplantation genetic testing for aneuploidy (niPGT-A) using cell-free DNA (cfDNA) present in the spent blastocyst medium (SBM) of human blastocysts has emerged as an alternative for classical preimplantation genetic testing for aneuploidy (PGT-A). The major benefit is to avoid possible damage to the trophectoderm and subsequently increase the implantation potential of the embryo. niPGT-A provides more information including the ploidy state of both trophectoderm and inner cell mass compared to invasive PGT-A in which only a few trophectoderm cells are assessed. This study was to report our first successful experience solely using niPGT-A to select embryos to transfer resulting in a successful delivery. This practical application is believed to be the first case report in Taiwan and can serve as an innovative model for other clinics to apply niPGT-A.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.